What Researchers Did
Researchers reviewed published studies on a rare but serious spinal cord injury called radiation myelopathy, which can happen after a type of precise radiation treatment for cancer that has spread to the spine.
What They Found
This is a narrative review of published literature on radiation myelopathy (RM) following spine stereotactic body radiation therapy (SBRT), covering dose limits, risk-reduction strategies, and treatment options. The review found limited published data with detailed spinal cord dosimetry for RM cases. It cites the HyTEC report's recommended maximum spinal cord dose (Dmax) associated with less than 5 percent risk of RM for 1 to 5 fraction SBRT treatments. For patients receiving repeat SBRT after prior conventional radiation, the review identifies SBRT spinal cord Dmax, cumulative spinal cord Dmax, and the time interval between treatments as factors linked to RM risk.
What This Means for Canadian Patients
The abstract mentions hyperbaric oxygen only as one of several treatment options doctors have used for radiation myelopathy, alongside corticosteroids and bevacizumab, but the review states none of these are supported by high quality evidence. It does not describe how hyperbaric oxygen works or how well it performs for this condition. Patients considering spine SBRT should discuss dose planning and risk-reduction strategies with their radiation oncology team.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
As a narrative review rather than a systematic review or clinical trial, it draws on limited published data, particularly detailed spinal cord dosimetry, and the treatments it discusses, including hyperbaric oxygen, are not backed by high quality evidence.